Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment

The CDKN2A locus, which is frequently deleted in pancreatic ductal adenocarcinoma (PDAC), encodes two tumor suppressors, ARF and INK4A, that may influence tumorigenesis through distinct mechanisms. Distinguishing their individual contributions to cancer could help improve the understanding of PDAC pathogenesis and potentially uncover targetable vulnerabilities. Moreover, while ARF is known to enhance p53 function, defining its p53-independent activities could elucidate processes that drive PDAC development. Here, we sought to understand ARF function in PDAC suppression. Expression and mutational patterns in human TCGA data indicated that CDKN2AARF and CDKN2AINK4A are commonly both affected by point mutations and/or deletions, suggesting that their combined inactivation contributes to PDAC development. In genetically engineered mouse models (GEMMs), Arf inactivation accelerated KRASG12D-driven PDAC development, both in the presence and absence of Trp53, demonstrating that ARF is a PDAC suppressor and can act in a p53-independent manner. Transcriptomic analyses of PDACs supported a p53-independent role for ARF, with ARF deficiency promoting extracellular matrix, collagen synthesis/assembly, and epithelial-mesenchymal transition gene expression programs. Accordingly, ARF-deficient PDACs displayed extensive remodeling of the tumor microenvironment (TME), associated with collagen deposition, increased tissue stiffness, and higher fibroblast content - hallmarks of aggressive and treatment-resistant PDAC stroma. Together, this study shows how ARF deficiency associated with CDKN2A inactivation sculpts the PDAC TME in a p53-independent fashion. Given the central role of the TME in PDAC progression and therapeutic resistance, these findings may provide insight critical for improving therapeutic interventions for PDAC.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-03-11
DOI
https://doi.org/10.1158/0008-5472.can-25-1969
Primary Topic
Cancer-related Molecular Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment

Hyo Young Choi, Wonyoung Choi, José A. Seoane, Laura D. Attardi et al.
Cancer Research
Cancer-related Molecular Pathways
article

Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment

Hyo Young Choi, Wonyoung Choi, José A. Seoane, Laura D. Attardi, Abigail S. Mulligan, Alberto Gatto, Mara H. Sherman, Monte M. Winslow, Brittany M. Flowers, Ghmkin Hassan, Sohinee Bhattacharyya, Dmitri A. Petrov, Sofia Ferreira, Gábor Boross, VM Weaver, Maria Farina-Morillas, Hannes S. Vogel, Andrew J. Aguirre, Laura D. Wood, D. Neil Hayes
article en

Abstract

The CDKN2A locus, which is frequently deleted in pancreatic ductal adenocarcinoma (PDAC), encodes two tumor suppressors, ARF and INK4A, that may influence tumorigenesis through distinct mechanisms. Distinguishing their individual contributions to cancer could help improve the understanding of PDAC pathogenesis and potentially uncover targetable vulnerabilities. Moreover, while ARF is known to enhance p53 function, defining its p53-independent activities could elucidate processes that drive PDAC development. Here, we sought to understand ARF function in PDAC suppression. Expression and mutational patterns in human TCGA data indicated that CDKN2AARF and CDKN2AINK4A are commonly both affected by point mutations and/or deletions, suggesting that their combined inactivation contributes to PDAC development. In genetically engineered mouse models (GEMMs), Arf inactivation accelerated KRASG12D-driven PDAC development, both in the presence and absence of Trp53, demonstrating that ARF is a PDAC suppressor and can act in a p53-independent manner. Transcriptomic analyses of PDACs supported a p53-independent role for ARF, with ARF deficiency promoting extracellular matrix, collagen synthesis/assembly, and epithelial-mesenchymal transition gene expression programs. Accordingly, ARF-deficient PDACs displayed extensive remodeling of the tumor microenvironment (TME), associated with collagen deposition, increased tissue stiffness, and higher fibroblast content - hallmarks of aggressive and treatment-resistant PDAC stroma. Together, this study shows how ARF deficiency associated with CDKN2A inactivation sculpts the PDAC TME in a p53-independent fashion. Given the central role of the TME in PDAC progression and therapeutic resistance, these findings may provide insight critical for improving therapeutic interventions for PDAC.

Cancer Research
University of Maryland, Baltimore (US), Memorial Sloan Kettering Cancer Center (US), Johns Hopkins University (US), University of Tennessee Health Science Center (US), Palo Alto University (US), University of California, San Francisco (US), Johns Hopkins Medicine (US), Vall d'Hebron Institut de Recerca (ES), Dana-Farber Cancer Institute (US), Vall d'Hebron Hospital Universitari (ES), HUN-REN Centre for Ecological Research (HU), Stanford Medicine (US), Johns Hopkins Hospital (US), Visual Health Information (US), University of Baltimore (US), University of San Francisco (US), Stanford University (US)
Good health and well-being
Openalex Percentile: Top 24%
Cancer-related Molecular Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.